2026 is going to be an exciting year for the GLP-1 space — you know it and I know it. Long dominated by the likes of Eli Lilly and Novo Nordisk, several other drugmakers are expected to challenge for ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have taken the weight-loss world by storm. Even beyond the healthcare world, Ozempic, Wegovy and Mounjaro have become household names as they have ...
From shifting grocery habits to new product opportunities, Circana’s insights reveal how brands and retailers can adapt to the rise of GLP-1 users The number of US adults taking GLP-1 drugs surged in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results